Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06005493

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Gastric Cancer Adenocarcinoma Of Esophagus Digestive System Diseases Digestive System Neoplasms Esophageal Adenocarcinoma Gastro-esophageal Junction Cancer Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Pancreatic Ductal Adenocarcinoma Stomach Diseases Stomach Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Research Site, Beijing, China

Loading trial locations.

About this study

This is a first-time in human, modular Phase I/II, open-label multicentre study of AZD5863 monotherapy administered intravenously (Module 1), or AZD5863 monotherapy administered subcutaneously (Module 2) in patients with advanced or metastatic solid tumors. Each module contains dose-escalation (Part A) and dose-expansion (Part B).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Age ≥ 18 at the time of signing the informed consent
  • Histologically confirmed diagnosis of adenocarcinoma of the stomach, gastro-esophageal junction, esophagus, or pancreas
  • Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Must show positive CLDN18.2 expression in tumor cells as determined by central immunohistochemistry (IHC)
  • Eastern Cooperative Oncology Group Performance status (ECOG PS): 0-1 at screening
  • Predicted life expectancy of ≥ 12 weeks
  • Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol
  • Contraceptive use by men or women should be consistent with local regulations, as defined by the protocol
  • Must have received at least one prior line of systemic therapy in the advanced/metastatic setting

Key Exclusion Criteria:

  • Unresolved toxicity from prior anticancer therapy of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2 except for those defined by the protocol
  • Participant experienced unacceptable cytokine release syndrome (CRS) or Immune Effector Cell Associated Neurotoxicity (ICANS) following prior T cell engagers (TCE) or chimeric antigen receptor T (CAR-T) cell therapy
  • Previous history of hemophagocytic lymphohistiocytosis (HLH) / macrophage activation syndrome (MAS)
  • Active or prior documented autoimmune or inflammatory disorders within 3 years of start of treatment
  • central nervous system (CNS) metastases or CNS pathology, as defined by the protocol, within 3 months prior to consent
  • Infectious disease including active human immunodeficiency virus (HIV), active hepatitis B/C, uncontrolled infection with EBV, uncontrolled active systemic fungal, bacterial or other infection
  • Cardiac conditions as defined by the protocol
  • History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention
  • Participant requires chronic immunosuppressive therapy
  • Participants on anticoagulation therapy with long-acting anticoagulants or other class of anticoagulants at therapeutic doses

Treatment and study plan

AZD5863

Drug

T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells

Primary outcomes

  1. The number of patients with adverse events

    Time frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy

    Number of patients with adverse events by system organ class and preferred term

  2. The number of patients with adverse events of special interest

    Time frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy

    Number of patients with adverse events of special interest by system organ class and preferred term

  3. The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.

    Time frame: From first dose of study drug until the end of Cycle 1

    A DLT is a toxicity as defined in the protocol that occurs from the first dose of study drug up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation.

  4. The number of patients with serious adverse events

    Time frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy

    Number of patients with serious adverse events by system organ class and preferred term

  5. Objective Response Rate (ORR)

    Time frame: From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)

    The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1). Dose expansion only.

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)

    The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1). Dose escalation only.

  2. Disease Control Rate (DCR)

    Time frame: From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)

    Percentage of patients with confirmed complete or partial response or having stable disease maintained for >= 11 weeks from first dose, according to response criteria in solid tumours (RECIST 1.1).

  3. Duration of response (DoR)

    Time frame: From the first documented response to progressive disease or death in the absence of disease progression (approx. 2 years)

    The time from the date of first response until date of disease progression or death in the absence of disease progression, according to response criteria in solid tumours (RECIST 1.1).

  4. Progression free Survival (PFS)

    Time frame: From the start of study treatment/date of randomization to progressive disease or death in the absence of disease progression (approx. 2 years)

    The time from the start of study treatment/date of randomization until RECIST 1.1 defined disease progression or death in the absence of disease progression.

  5. Overall Survival (OS)

    Time frame: From the start of study treatment/date of randomization to death (to be followed-up for approx. 2 years)

    The time from the start of study treatment/date of randomization until death due to any cause.

  6. Pharmacokinetics of AZD5863: Maximum plasma concentration of the study drug (Cmax)

    Time frame: From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)

    Maximum observed plasma concentration of the study drug

  7. Pharmacokinetics of AZD5863: Area Under the concentration-time curve (AUC)

    Time frame: From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)

    Area under the plasma concentration-time curve

  8. Pharmacokinetics of AZD5863: Clearance

    Time frame: From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)

    A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time.

  9. Pharmacokinetics of AZD5863: Terminal elimination half-life (t 1/2)

    Time frame: From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)

    Terminal elimination half life.

  10. Immunogenicity of AZD5863

    Time frame: From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)

    The number and percentage of participants who develop anti-drug antibodies (ADAs) measured in serum

  11. Preliminary antitumor activity with target expression pre- and post-delivery of AZD5863

    Time frame: From time of Informed consent, at predefined intervals (including screening, on-treatment or end of treatment) throughout the study (over approx. 2 years)

    Measure CLDN18.2 expression (IHC) in baseline and/or on-treatment tumor biopsies and correlate with clinical outcome

Study contacts

Contact information is provided by the study sponsor or research team.

AstraZeneca Clinical Study Information Center

CONTACT

[email protected]

1-877-240-9479

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Aug 22, 2023
Registry last updated
Feb 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.